Protocol Status: PUBLISHED
Protocol:
Version: 2026.01
Effective Date:
Last Reviewed:
Medical Director Approval:
Clinical Note: This content reflects current GCEMS clinical guidelines as of the dates listed above. If content appears inconsistent with current policy, use the most recent approved guideline and notify leadership for correction.

Toradol

(Ketorolac)

 

GCEMS Protocol:

 

  • Adult\ Ped Pain Management

 

Indications:

 

  • Severe pain in selective situations

 

Contraindications:

 

  • Known hypersensitivity
  • patients with advanced renal impairment
  • patients at risk for renal failure due to volume depletion.

 

Side Effects:

 

  • No side effects have occurred except with overdoses

 

Adult:

 

  • 15 mg IV\ 30 mg IM

 

 

Pediatric:

 

  • 2 years of age or older only
  • 0.5 mg\kg, max of 15 mg IV\30 mg IM